FI105812B - Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI105812B
FI105812B FI931667A FI931667A FI105812B FI 105812 B FI105812 B FI 105812B FI 931667 A FI931667 A FI 931667A FI 931667 A FI931667 A FI 931667A FI 105812 B FI105812 B FI 105812B
Authority
FI
Finland
Prior art keywords
alkyl
indole
aryl
ylmethyl
hydrogen
Prior art date
Application number
FI931667A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI931667A (fi
FI931667A0 (fi
Inventor
Martin James Wythes
John Eugene Macor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24393510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI105812(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of FI931667A publication Critical patent/FI931667A/fi
Publication of FI931667A0 publication Critical patent/FI931667A0/fi
Application granted granted Critical
Publication of FI105812B publication Critical patent/FI105812B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI931667A 1990-10-15 1993-04-14 Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi FI105812B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59792890A 1990-10-15 1990-10-15
US59792890 1990-10-15
PCT/US1991/007194 WO1992006973A1 (en) 1990-10-15 1991-10-08 Indole derivatives
US9107194 1991-10-08

Publications (3)

Publication Number Publication Date
FI931667A FI931667A (fi) 1993-04-14
FI931667A0 FI931667A0 (fi) 1993-04-14
FI105812B true FI105812B (fi) 2000-10-13

Family

ID=24393510

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931667A FI105812B (fi) 1990-10-15 1993-04-14 Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi

Country Status (33)

Country Link
EP (1) EP0592438B1 (es)
JP (2) JP2575272B2 (es)
KR (1) KR0179053B1 (es)
CN (1) CN1039322C (es)
AT (1) ATE157361T1 (es)
AU (1) AU651637B2 (es)
BG (1) BG61975B1 (es)
BR (2) BR9106978A (es)
CA (1) CA2091562C (es)
DE (3) DE69127468T2 (es)
DK (1) DK0592438T5 (es)
EG (1) EG20224A (es)
ES (1) ES2104733T3 (es)
FI (1) FI105812B (es)
GR (1) GR3025087T3 (es)
HU (2) HU225055B1 (es)
IE (1) IE913555A1 (es)
IL (3) IL115117A (es)
LU (1) LU90902I2 (es)
MX (1) MX9101606A (es)
MY (1) MY111683A (es)
NL (1) NL300070I2 (es)
NO (3) NO305121B1 (es)
NZ (2) NZ270675A (es)
OA (1) OA09874A (es)
PL (3) PL170330B1 (es)
PT (1) PT99218B (es)
RO (1) RO111767B1 (es)
RU (1) RU2095360C1 (es)
SG (1) SG54270A1 (es)
WO (1) WO1992006973A1 (es)
YU (1) YU48088B (es)
ZA (1) ZA918156B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
UA41297C2 (uk) * 1991-11-25 2001-09-17 Пфайзер, Інк. Похідні індолу, фармацевтична композиція і спосіб лікування
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
BR9306201A (pt) * 1992-04-07 1998-06-23 Pfizer Derivados de indol como agonistas 5-ht1
ATE148465T1 (de) * 1992-04-10 1997-02-15 Pfizer Acylaminoindolderivate als 5-ht1 agonisten
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
CN1121348A (zh) * 1993-04-22 1996-04-24 辉瑞研究及发展公司 吲哚衍生物作为5-ht1类激动剂用于治疗周期性偏头痛
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ES2070772B1 (es) * 1993-08-09 1996-02-16 Pfizer Derivados de acilaminoindol
EP0716649B1 (en) * 1993-08-31 1998-09-09 Pfizer Inc. 5-arylindole derivatives
AU3162695A (en) * 1994-08-03 1996-03-04 Asta Medica Aktiengesellschaft Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
AU726560B2 (en) * 1994-10-12 2000-11-09 Pfizer Research And Development Company, N.V./S.A. Use of indole derivatives for the treatment of various diseases
ATE224388T1 (de) * 1994-10-12 2002-10-15 Pfizer Res & Dev Indolderivate zur behandlung von migräne
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
AU3170099A (en) * 1998-04-16 1999-11-08 Yamanouchi Pharmaceutical Co., Ltd. Remedies for obesity
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP2000336074A (ja) 1999-03-24 2000-12-05 Sumitomo Chem Co Ltd ［２−（アリールスルホニル）エテニル］ベンゼン誘導体の製造方法
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2382116A1 (en) * 1999-08-26 2001-03-08 Fujisawa Pharmaceutical Co., Ltd. Process for the preparation of indole derivatives or salts thereof
GB9923314D0 (en) * 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
US20030166704A1 (en) 2000-12-20 2003-09-04 Pfizer Inc. New process
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
EP3168218B1 (en) 2001-08-15 2018-11-14 Pharmacia & Upjohn Company LLC A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
AU2006257647A1 (en) 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasites
WO2006079999A2 (en) * 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
WO2009142771A2 (en) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
WO2010005507A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
IT1393700B1 (it) * 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011024039A1 (en) * 2009-08-25 2011-03-03 Ramesh Babu Potluri Synthesis of novel 5-(2-(phenylsulfonyl)ethyl)-1h-indole derivatives
US8754239B2 (en) 2010-01-19 2014-06-17 Sms Pharmaceuticals Limited Process for preparing eletriptan hydrobromide having α-form
CN102606426B (zh) * 2012-03-02 2014-05-21 王仲彦 踏步健身发电装置
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
CN103408535B (zh) * 2013-08-13 2016-03-02 张家港威胜生物医药有限公司 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺
CN107530318A (zh) 2015-03-02 2018-01-02 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2017125351A1 (en) 2016-01-21 2017-07-27 Laboratorios Lesvi Sl Process for preparing (( r)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)-1h-indole
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TR201616365A1 (tr) 2016-11-14 2018-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deksketoprofen ve eletri̇ptanin oral farmasöti̇k kompozi̇syonlari
TR201619983A2 (tr) 2016-12-29 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
KR102129947B1 (ko) 2018-06-08 2020-07-03 김종창 콘크리트 타설을 위한 입체형 와이어 메쉬
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
US20230346746A1 (en) 2020-01-22 2023-11-02 Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, S.A. Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74527C (es) *
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
IL115117A (en) 1996-11-14
FI931667A (fi) 1993-04-14
EG20224A (en) 1997-12-31
AU651637B2 (en) 1994-07-28
IL115117A0 (en) 1995-12-08
NO2001019I1 (no) 2001-12-03
EP0592438B1 (en) 1997-08-27
OA09874A (en) 1994-09-15
BG97632A (bg) 1994-03-31
LU90902I2 (fr) 2002-06-26
PT99218B (pt) 1999-04-30
RO111767B1 (ro) 1997-01-30
DE9190141U1 (de) 1993-07-15
PL170330B1 (pl) 1996-11-29
NL300070I1 (nl) 2002-02-01
JPH05507288A (ja) 1993-10-21
DE69127468T2 (de) 1998-01-02
CN1039322C (zh) 1998-07-29
PL168919B1 (pl) 1996-05-31
NO985607D0 (no) 1998-12-01
SG54270A1 (en) 1998-11-16
CA2091562A1 (en) 1992-04-16
PT99218A (pt) 1992-09-30
NL300070I2 (nl) 2002-03-01
NO931378L (no) 1993-04-14
JP2575272B2 (ja) 1997-01-22
CN1062529A (zh) 1992-07-08
MY111683A (en) 2000-11-30
HU225055B1 (en) 2006-05-29
EP0592438A1 (en) 1994-04-20
KR0179053B1 (ko) 1999-03-20
BG61975B1 (bg) 1998-11-30
ATE157361T1 (de) 1997-09-15
BR1100080A (pt) 2000-06-06
MX9101606A (es) 1992-06-05
YU48088B (sh) 1997-01-08
DK0592438T5 (da) 1999-12-06
DK0592438T3 (da) 1997-09-29
ZA918156B (en) 1993-04-14
DE69127468D1 (de) 1997-10-02
YU165391A (sh) 1994-01-20
JPH093063A (ja) 1997-01-07
IL99701A0 (en) 1992-08-18
CA2091562C (en) 2001-03-27
DE10299004I2 (de) 2006-03-16
NZ240217A (en) 1995-05-26
AU8950491A (en) 1992-05-20
NZ270675A (en) 1997-07-27
JP2677777B2 (ja) 1997-11-17
HUT64326A (en) 1993-12-28
IE913555A1 (en) 1992-04-22
NO305121B1 (no) 1999-04-06
FI931667A0 (fi) 1993-04-14
GR3025087T3 (en) 1998-01-30
IL99701A (en) 1996-10-31
DE10299004I1 (de) 2002-05-08
HU9301098D0 (en) 1993-07-28
NO985607L (no) 1998-12-01
RU2095360C1 (ru) 1997-11-10
PL169987B1 (en) 1996-09-30
WO1992006973A1 (en) 1992-04-30
BR9106978A (pt) 1993-09-28
ES2104733T3 (es) 1997-10-16
NO931378D0 (no) 1993-04-14

Similar Documents

Publication Publication Date Title
FI105812B (fi) Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi
US5545644A (en) Indole derivatives
US5578612A (en) Indole derivatives
KR100857671B1 (ko) 화학적 화합물
US5607951A (en) Indole derivatives
HU208132B (en) Process for producing 3-arylcarbonyl-1h-indole derivatives and pharmaceutical compositions comprising same
WO2014002052A1 (en) Pyrrolidine derivatives and their use as complement pathway modulators
ZA200603181B (en) 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
US20040157818A1 (en) Cxcr4-antagonistic drugs composed of nitrogen-containing compound
US5559129A (en) Indole derivatives
KR0183396B1 (ko) 3-아릴카르보닐-1-아미노알킬-1h-인돌류,이를 함유하는 항녹내장 조성물 및 이의 제조방법
TW199860B (es)
US5559246A (en) Indole derivatives
US5319096A (en) (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
JP6844822B2 (ja) 疼痛に対して活性を有する置換モルホリン誘導体
JP6884973B2 (ja) 疼痛に対して活性を有するオキサジアザスピロ化合物
EP0906308A1 (en) Azetidine, pyrrolidine and piperidine derivatives as 5-ht1d receptor agonists
CA2350089C (en) Indole derivatives
NZ612899B2 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)

Legal Events

Date Code Title Description
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L191

Extension date: 20151213

MA Patent expired